SCHEMBL3097702

SCHEMBL3097702

CCN(C(=O)C(Cc1cnn(Cc2ccc(Cl)nc2)c1)C(=O)O)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
ALDH1A1 P00352 3/20 0.37
TP53 P04637 1/20 0.37
HSD17B10 Q99714 1/20 0.36
KMT2A Q03164 3/20 0.36
MEN1 O00255 1/20 0.36
ATM Q13315 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ACACB O00763 1/20 0.36
CPB2 Q96IY4 1/20 0.35
PPARG P37231 1/20 0.35
HTT P42858 1/20 0.35
GLA P06280 1/20 0.34
TSHR P16473 1/20 0.34
KDM1A O60341 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
AGTR2 P50052 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3089260 0.92 KMT2A (0.39) GAAMAPTALDH1A1TP53HSD17B10
SCHEMBL3087759 0.92 LMNA (0.38) GAAMAPTALDH1A1HSD17B10KMT2A
SCHEMBL3097169 0.90 ALDH1A1 (0.40) MAPTALDH1A1TP53ACACBHTT
SCHEMBL3103633 0.87 LMNA (0.46) MAPTALDH1A1TP53SMN1; SMN2ACACB
SCHEMBL3085699 0.87 GAA (0.43) GAAMAPTALDH1A1HSD17B10KMT2A
SCHEMBL3085097 0.84 TP53 (0.43) MAPTALDH1A1TP53KMT2AMEN1
SCHEMBL3085954 0.84 GAA (0.32) GAAMAPTALDH1A1KMT2AMEN1
SCHEMBL3085957 0.84 GAA (0.32) GAAMAPTALDH1A1KMT2AMEN1
SCHEMBL3093117 0.83 ALDH1A1 (0.42) MAPTALDH1A1TP53KMT2AMEN1
SCHEMBL3470506 0.83 GAA (0.48) GAAMAPTALDH1A1HSD17B10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
CN-101784520-A Novel malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORP 2010-07-21 CN disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 GAA 272/4885MAPT 2813/4885ALDH1A1 617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.